JNJ
229.41
+0.89%↑
ISRG
499.72
-0.78%↓
ABT
109.65
+0.38%↑
RDY
13.46
+0.45%↑
NEOG
10.44
+2.25%↑
JNJ
229.41
+0.89%↑
ISRG
499.72
-0.78%↓
ABT
109.65
+0.38%↑
RDY
13.46
+0.45%↑
NEOG
10.44
+2.25%↑
JNJ
229.41
+0.89%↑
ISRG
499.72
-0.78%↓
ABT
109.65
+0.38%↑
RDY
13.46
+0.45%↑
NEOG
10.44
+2.25%↑
JNJ
229.41
+0.89%↑
ISRG
499.72
-0.78%↓
ABT
109.65
+0.38%↑
RDY
13.46
+0.45%↑
NEOG
10.44
+2.25%↑
JNJ
229.41
+0.89%↑
ISRG
499.72
-0.78%↓
ABT
109.65
+0.38%↑
RDY
13.46
+0.45%↑
NEOG
10.44
+2.25%↑
24h
Current
Min
Max
Income | -75M -544K |
|---|---|
Sales | 182K 26M |
P/E Sector Avg | 19.192 90.422 |
Profit margin | -2.087 |
Employees | 59 |
EBITDA | 73M 1.5M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +166.67% upside |
Next Earnings | 10 Mar 2026 |
|---|
Market Cap | -65M 508M |
|---|---|
Previous open | 0 |
Previous close | 0 |
Past performance is not a reliable indicator of future results.
27 Feb 2025, 15:29 UTC
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 24 USD 166.67%
High 26 USD
Low 21 USD
Based on 6 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
6 ratings
6
Buy
0
Hold
0
Sell
Based on 6 analysts giving stock ratings to KemPharm Inc - Dist in the past 3 months.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$